Official websites use. Share sensitive information only on official, secure websites. Englische Version. These guidelines are also consistent with the results of the first European guidelines for sclerotherapy dating from [ 1 ]. These guidelines consider the current state of the literature, but not in every case the different conditions of approval of the various drugs. Sclerotherapy is the targeted chemical ablation of a varicose vein by intravenous injection of a liquid or foam sclerosant [ 1 , 2 ].
The sclerosant destroys the endothelium of the vein and possibly other regions of the vein wall, and is deactivated by blood components and circulating cells [ 1 , 2 ]. After successful sclerotherapy the varicose vein is transformed in the long term into a string of connecting tissue, in a process known as sclerosis [ 3 β 6 ]. The objective of sclerotherapy is not thrombosis of the vein, since re-channelling may occur after this process, but its transformation into a string of connecting tissue.
Re-channelling of this is impossible, so the functional outcome is equivalent to removal of the vein or endovenous thermal ablation. Incompetent saphenous veins [ 5 , 7 β 18 ].
Varicose tributaries [ 19 , 20 ]. Incompetent perforator veins [ 19 , 21 β 24 ]. Reticular varices [ 8 , 20 , 25 β 30 ].
Spider veins telangiectasia [ 8 , 20 , 25 β 30 ]. New, remaining and recurrent varicose veins after previous operations [ 19 , 31 β 39 ]. Genital and perigenital varices [ 31 , 40 β 42 ]. Varicose veins veins with reflux around a leg ulcer [ 43 β 50 ]. Venous malformations [ 51 β 57 ].
